TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
   Verona Pharma to present at 7th Annual Biotech ShowcaseT in San Francisco 
 
12 January 2015, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
announces that Company Chief Executive Officer, Dr Jan-Anders Karlsson, will be 
presenting at the Biotech ShowcaseT 2015 Conference, 12-14 January 2015, San 
Francisco, CA. 
 
Details of Verona Pharma's presentation are as follows: 
 
Event:         Biotech ShowcaseT 2015 Conference 
 
Date:          13 January 2015 
 
Time:          16.30 PST 
 
Location:      Room Mission II: Parc 55 Wyndham San Francisco Union Square 
               Hotel 
 
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech 
Showcase is an investor and partnering conference devoted to providing private 
and public biotechnology and life sciences companies an opportunity to present 
to, and meet with, investors and pharmaceutical executives during the course of 
one of the industry's largest annual healthcare investor conferences. Now in 
its seventh year, Biotech Showcase is expected to attract upwards of 1,500 
attendees. 
 
Further details on the presentations and timings can be accessed via the 
following website: http://www.ebdgroup.com/bts/presenters/prs_comps.php 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                       Tel: +44 (0) 20 3283 4200 
 
Jan-Anders Karlsson, CEO 
 
FTI Consulting                          Tel: +44 (0)20 3727 1000 
 
Julia Phillips / Simon Conway 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value. This includes the 
very significant markets for COPD and asthma maintenance therapy. The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the Cystic Fibrosis Trust. 
 
About Demy-Colton Life Science Advisors 
 
Demy-Colton Life Science Advisors is focused exclusively on facilitating the 
growth of the life science industry. Now going into its fifth year, Demy-Colton 
has developed a number of high-value added conferences to address the business 
and development needs of the biotechnology industry; it provides partnering 
services and it has helped launch a unique investor website and newsletter. For 
more information please visit www.demy-colton.com. 
 
About EBD Group 
 
EBD Group is the leading partnering firm for the global life science industry. 
Since 1993, biotech, pharma and medical device companies have leveraged EBD 
Group's partnering conferences, technology and services to identify business 
opportunities and develop strategic relationships essential to their success. 
For more information please visit www.ebdgroup.com or follow EBD Group on 
Twitter at twitter.com/ebdgroup. 
 
 
 
END
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Verona Pharma Charts.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Verona Pharma Charts.